| Lundbeck (Schweiz) AG - Abilify Maintena 300 mg, Depot-Injektionssuspension in einer Fertigspritze | | 65774 | | 02 | | Abilify Maintena 300 mg | | Depot-Injektionssuspension in einer Fertigspritze | | N05AX12 | | Aripiprazol | | 15.03.2016 | | |
| | Composition | | Praeparatio cryodesiccata: aripiprazolum 300 mg, aripiprazolum monohydricum, carmellosum natricum, mannitolum, natrii dihydrogenophosphas monohydricus, natrii hydroxidum, ad pulverem.
Solvens: aqua ad iniectabile.
Solutio reconstituta: aripiprazolum 300 mg ut aripiprazolum monohydricum, carmellosum natricum, mannitolum, natrii dihydrogenophosphas monohydricus, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 1.5 ml corresp. natrium max. 1.6 mg. | | Packungsbestandteile | | Praeparatio cryodesiccata: | | Depot-Injektionssuspension in einer Fertigspritze | | | | | | Principe actif | Concentr. |
|---|
| Aripiprazole | 300 mg | | Aripiprazolum Monohydricum | |
| | | | Agents auxilliaires |
|---|
| Carmellose Sodique | | Mannitol | | Sodium Dihydrogenophosphate Monohydrate | | Sodium Hydroxide |
|
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 002 | seringue prête | DDP | DDP | B | | Oui |
|
|
